With respect to TRAIL signaling, it has been shown that type-II cancer cells can acquire resistance to TRAIL-induced apoptosis by loss of Bax82 or increased expression of Bcl-2,83 Bcl-xL84 or Mcl-185 (Figure 3). This evidence concerns the gene BCL2 and cancer.